Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ) just unveiled an announcement.
Shanghai Junshi Biosciences Co., Ltd. announced the approval of its supplemental new drug application for toripalimab as a first-line treatment for unresectable or metastatic melanoma. This approval marks a significant milestone as toripalimab becomes the first domestic anti-PD-1 monoclonal antibody approved for advanced melanoma in China, addressing an urgent clinical need. The approval is based on positive results from the MELATORCH study, which demonstrated improved progression-free survival and overall survival rates compared to traditional chemotherapy. This development enhances Junshi Biosciences’ position in the oncology market and provides a new treatment option for melanoma patients, potentially impacting the company’s market presence and stakeholder interests.
More about Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. is a biotechnology company based in China, focusing on the development and marketing of innovative therapies, particularly monoclonal antibodies. The company has a strong presence in the pharmaceutical industry, with a portfolio that includes toripalimab, a PD-1 monoclonal antibody, which has been approved for multiple indications in China and other regions.
YTD Price Performance: 38.00%
Average Trading Volume: 2,229,121
Technical Sentiment Signal: Sell
Current Market Cap: HK$28.02B
Learn more about 1877 stock on TipRanks’ Stock Analysis page.